Alfred L. Garfall, MD, discusses long-term follow-up data from the MajesTEC-1 study presented at ASCO 2024. 1. Discuss the data presented at ASCO 2024 on long-term follow-up of patients receiving ...
Please provide your email address to receive an email when new articles are posted on . DESTIN, Fla. — Rheumatologists should consider tapering tocilizumab for patients with giant cell arteritis in ...
CHICAGO — Tocilizumab (TCZ) appears to be more effective than methotrexate (MTX) for giant cell arteritis (GCA) in maintaining remission and preventing relapse at 52 weeks, according to new data from ...
Subcutaneous tocilizumab, alone or with methotrexate, showed superior efficacy over methotrexate monotherapy in treating rheumatoid arthritis in Chinese patients. The trial demonstrated higher ACR20 ...
Subcutaneous tocilizumab, either as monotherapy or in combination with methotrexate, demonstrated greater efficacy than methotrexate alone and was well tolerated in patients with active rheumatoid ...
INCHEON, South Korea, Oct. 2, 2025 /PRNewswire/ -- Celltrion, Inc. today announced that AVTOZMA® (tocilizumab-anoh) intravenous (IV) formulation is now available to patients in the United States.
Strengthens and expands U.S. biosimilars immunology portfolio with multi-indication arthritis treatment “Biosimilars continue to be a key growth driver for Organon, and this acquisition complements ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results